Loading, Please Wait...
Fort Lauderdale, FL, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), (the “Company” or “BioStem Technologies”) a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine that exponentially improve, extend, and transform the quality of life for patients, announced today that it has engaged Maxim Group LLC (“Maxim”), a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services to the Company. Maxim will focus on assisting BioStem Technologies with its strategies for maximizing shareholder value through its full scope of investment banking services.
Of the partnership, Jason Matuszewski, Chief Financial Officer of BioStem Technologies stated, “We are very pleased to have partnered with Maxim. Maxim is a well-established investment banking firm with a Reg A+ platform and strong capital-raising capabilities. We believe that Maxim’s Reg A+ platform and financing resources, combined with its ability to assist us on the front of strategic advisory, will benefit us greatly with the successful and efficient execution of our strategic growth plan. It is our desire that Maxim’s Reg A+ platform, and their financing capabilities in particular, will open up new doors for BioStem Technologies to take advantage of the numerous growth opportunities that are presenting themselves to us.”
Added Andrew Van Vurst, Chief Operating Officer of BioStem Technologies: “We look to continue our accelerated growth trajectory with multiple Investigational New Drugs and New Drug Applications in the pharmaceutical and biopharmaceutical sector, along with seeking strategic acquisitions that will help fortify our product portfolio and add multiple revenue verticals in the life science sector. We are very excited to work with Maxim as a key partner of our company.”
About Maxim Group LLC: Maxim Group LLC is a leading full-service investment banking, securities and wealth management firm headquartered in New York. Maxim provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed income and derivative sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA), Securities Insurance Protection Corporation (SIPC), NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” include risks and uncertainties, and describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the Company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the Company with OTC Markets. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: email@example.com Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst firstname.lastname@example.org